SDZ-DJN 608 en es it fr

SDZ-DJN 608 Brand names, SDZ-DJN 608 Analogs

SDZ-DJN 608 Brand Names Mixture

  • No information avaliable

SDZ-DJN 608 Chemical_Formula


SDZ-DJN 608 RX_link

SDZ-DJN 608 fda sheet


SDZ-DJN 608 msds (material safety sheet)

SDZ-DJN 608 Synthesis Reference

No information avaliable

SDZ-DJN 608 Molecular Weight

317.423 g/mol

SDZ-DJN 608 Melting Point

No information avaliable

SDZ-DJN 608 H2O Solubility

Practically insoluble

SDZ-DJN 608 State


SDZ-DJN 608 LogP


SDZ-DJN 608 Dosage Forms

Tablets (60, 120 mg)

SDZ-DJN 608 Indication

For use as monotherapy to lower blood glucose in patients with Type 2 diabetes (non-insulin dependent diabetes mellitus, NIDDM) whose hyperglycemia cannot be adequately controlled by diet and physical exercise and who have not been chronically treated with other anti-diabetic agents. Also indicated for use in combination with metformin.

SDZ-DJN 608 Pharmacology

Nateglinide is an amino-acid derivative that lowers blood glucose levels by stimulating insulin secretion from the pancreas. This action is dependent upon functioning beta-cells in the pancreatic islets.

SDZ-DJN 608 Absorption

Rapidly absorbed following oral administration prior to a meal, absolute bioavailability is estimated to be approximately 73%.

SDZ-DJN 608 side effects and Toxicity

An overdose may result in an exaggerated glucose-lowering effect with the development of hypoglycemic symptoms.

SDZ-DJN 608 Patient Information

SDZ-DJN 608 Organisms Affected

Humans and other mammals